drugset / Trial / NCT06693765

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants

NCT06693765

Phase 1 Completed 41 enrolled AstraZeneca Parexel · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A study to investigate the pharmacokinetics, safety, and tolerability of AZD4144 in participants with severe renal impairment, end-stage kidney disease, and in healthy participants.

Timeline

Start
2024-11-18
Primary completion
2025-04-23
Completion
2025-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4144 Unknown Oral